Researchers rewired ribosomes to build one protein and nothing else

Every living cell depends on ribosomes, the molecular machines that read genetic instructions and stitch amino acids together into proteins. A typical ribosome is a generalist, capable of picking up the blueprint for any of the thousands of proteins a cell might need at a given moment, decoding whichever messenger RNA molecule happens to drift into range and translating its sequence into a chain of amino acids. Researchers at the University of Illinois Chicago have now built the opposite: a ribosome engineered to specialize permanently in a single protein. The platform, described in a study published in Nature and led by corresponding author Alexander Mankin, could give synthetic biologists a new way to manufacture designer drugs and other engineered proteins without relying on a cell’s normal, unspecialized machinery.

Splicing the recipe directly into the machine

Called Ribo-M, the platform physically links a ribosome to the messenger RNA that carries instructions for one specific protein, rather than leaving the ribosome to locate that messenger RNA on its own somewhere in the cell. “Natural ribosomes need to look around the cell to find the blueprint or the recipe for any of the hundreds of proteins to synthesize,” said study author Kasra Alizadeh, a doctoral graduate of the university’s Retzky College of Pharmacy and now a postdoctoral fellow in its College of Engineering. Mankin, a distinguished professor at the Retzky College of Pharmacy, said the team “decided to overcome this problem by incorporating the message into the ribosome itself,” building a machine that never has to search for its instructions because it already carries them. In a normal cell, a ribosome and its target messenger RNA meet essentially by chance; Ribo-M removes that randomness by fusing the two components before translation ever begins, so the ribosome’s only job becomes producing more of the one protein it was built to make.

Years of trial and error to find a working design

Getting a ribosome to function while permanently tethered to one messenger RNA was not straightforward, according to a summary of the findings. The researchers generated tens of thousands of ribosome variants and screened thousands of bacterial colonies before identifying a configuration that worked reliably, according to Alizadeh. Once the team had a functional design, it tested whether the specialized ribosome could actually manufacture useful proteins rather than simply hold onto its designated genetic message. “Our engineered ribosomes are specialized,” Alizadeh said. “They always carry with them the recipe for one specific protein and only focus on making that protein without having to waste time looking around.”

Proving the concept with three different proteins

To demonstrate that Ribo-M was not a one-trick system, the researchers used it to produce several distinct proteins: a protein that generates green fluorescence, a protein that confers antibiotic resistance, and a light-producing enzyme. Each choice served as a different kind of functional test: the fluorescent protein offered a visual signal, the antibiotic-resistance protein offered a selectable trait that only survives if the protein actually works, and the light-producing enzyme required correctly folded, catalytically active output rather than a passive structural molecule. Success across three unrelated protein types suggested the platform could be adapted to a wide range of genetic targets rather than working only for the specific sequence used during development. Mankin compared the approach to medical specialization: “You have a general physician, who has to know a little bit about every single disease. But if you need to have brain surgery, you better go to the one who has specialized in this particular task.”

A path toward designer peptide drugs

The immediate motivation for building a dedicated protein-making ribosome is biotechnology. A specialized ribosome, freed from the demands of general-purpose protein production, could in principle be tuned to incorporate nonstandard amino acids not found in nature, opening the door to proteins with new stability or new functions, since a specialized ribosome no longer has to preserve the broad decoding rules a general-purpose ribosome needs to keep making every other protein in the cell correctly. Mankin pointed to therapeutic antibodies as one target, saying such ribosomes “will be able, for example, to make therapeutic antibodies that survive longer in the body.” The team also cited semaglutide, the peptide-based active ingredient in drugs such as Ozempic, as an example of the kind of molecule that currently requires complex manufacturing and that specialized ribosomes might eventually help produce more efficiently. Mankin was careful to temper expectations about how close that future is, describing the current Ribo-M as a prototype: “This is not even the Wright brothers’ airplane. This is the bicycle with wings.”

A possible window into life’s earliest protein-making systems

Beyond its industrial potential, the design has a second, more speculative payoff. Because Ribo-M fuses the protein-making machinery and its genetic instructions into a single unit, it offers researchers a physical model for how the earliest protein synthesis systems might have operated before cells evolved large populations of free-floating ribosomes and messenger RNAs. Alizadeh described the work as the start of a broader research direction, saying the specialized ribosomes “can serve as an exclusive protein synthesis platform, which can be fine-tuned by synthetic biologists for the production of designer drugs, enzymes and other proteins.” That framing casts Ribo-M less as a finished tool than as a chassis other labs can adapt, swapping in a different messenger RNA sequence to redirect the same specialized machinery toward a new target protein. Dorota Klepacki and Nora Vázquez-Laslop, both of the University of Illinois Chicago, also contributed to the study.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview